Results revealed that the low-PCBP1 expression group had a clearly poor disease-free survival (11.8 % vs. 45.3 %; log rank P = 0.01; shown in Fig. 4a) and overall survival (18.2 % vs. 42.4 %; log rank P = 0.032; shown in Fig. 4b), confirming that PCBP1 could be an additional predictor in AML prognosis. The gene discussed is PCBP1; the disease is acute myeloid leukemia.